Phase II of Combined Treatment of Cetuximab and Paclitaxel in Basal Like Breast Carcinoma
Basal like breast carcinoma is a Her2, ER PR negative breast cancer. It is notable for the
high percentage of EGFR expression in this tumor subtype.Weekly taxol (paclitaxel) is widely
used in breast cancer patients with metastatic disease. Erbitux (cetuximab) is a monoclonal
antibody that shown its ability to enhance activity of chemotherapy in colon carcinoma. Thus
we wanted to combine the use of anti EGFR therapy in the form of Erbitux (cetuximab) with
the widely used weekly taxol chemotherapy for the treatment of women with basal like breast
carcinoma. This is a small phase II study that will hopefully provide initial data as to the
general tolerability and response rate of this combination in this disease. Furthermore,
pathologic analysis will be used to try and assess relation of response with the presence
of immunohistochemical markers such as EGFR expression.
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
tumor markers tumor size by ct
two years
Hovav Nechushtan, MD/PHD
Principal Investigator
Hadassah Ein Kerem Jerusalem
Israel: Israeli Health Ministry Pharmaceutical Administration
cpblb1-HMO-CTIL
NCT00353717
November 2006
September 2009
Name | Location |
---|